Pharmacokinetics of orally administered antifungals in onychomycosis

International Journal of Dermatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 20-27

  De Doncker, Piet ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG EXCRETION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; HUMANS; INTESTINAL ABSORPTION; NAILS; ONYCHOMYCOSIS;

EID: 0032888518     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00010.x     Document Type: Article

References (56)

1. Van Cutsem J. The antifungal activity of ketoconazole. Am J Med 1983; 74: 9-15.
2. De Doncker P. Pharmacokinetics in Onychomycosis. In: Jacobs PH, Nall L, eds. Fungal Disease: Biology Immunology and Diagnosis. New York: Marcel Dekker, Inc., 1997: 517-545.
3. Riegelman S. Clinical evaluation of the effect of formulation variables on therapeutic performance of drugs. Drug Inform Bull 1969; 3: 59.
4. Chiou WL, Riegelman S. Absorption characteristics of solid dispersed and micronized griseofulvin in man. J Pharm Sci 1971; 60: 1376-1380.
5. Schäfer-Korting M, Korting HC, Mutschler E. Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Eur J Clin Pharmacol 1985; 29: 109-113.
6. Korting HC, Schäfer-Korting M, Zienicke H, et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with itraconazole. Antimicrob Ag Chemoth 1993; 37: 2064-2068.
7. Huang Y-C, Colaizzi JL, Bierman RH, et al. Pharmacokinetics and dose proportionally of ketoconazole in normal volunteers. Antimicrob Ag Chemoth 1986; 30: 206-210.
8. Lewawongs P, barone JA, Colaizzi JL, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988; 7: 228-235.
9. Jenssen JC. Pharmacokinetics of terbinafine in humans. J Dermatol Treatment 1990; 1 (Suppl. 2): 15-18.
10. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-284.
11. Gupta AK, Sauder DN, Shear NH. Anitfungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-933.
12. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and man. Antimicrob Ag Chemother 1985; 28: 648-653.
13. Brammer KW, Tarbit MH. A review of the pharmacokinetics of fluconazole (UK-49,858) in laboratory animals and man. In: Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: JR Prous Science Publishers SA, 1987: 141-150.
14. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-344.
15. Rich P, Scher RK, Breneman D, et al. Pharmacokinetics of three doses (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38: S103-S109.
16. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 (Suppl.): 67-87.
17. Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987; 9 (Suppl. 1): 15-32.
18. Bates TR, Sequeira JAL. Use of 24-hr urinary excretion to assess the bioavailability of griseofulvinin humans. J Pharm Sci 1975; 64: 709.
19. Kabasakalian P. Parameters affecting absorption of griseofulvin in a human subject using urinary metabolite excretion data. J Pharm Sci 1970; 59: 595.
20. Heel RC. Pharmacokinetic properties. In: Levine HB, ed. Ketoconazole in the Management of Fungal Disease. Sydney: ADIS Press, 1982: 67-73.
21. Gascoigne EW, Barton GJ, Michaels M, et al. The kinetics of ketoconazole in animals and man. Clin Res Rev 1981; 1: 177-187.
22. Battig FA, Nefzger M, Schultz G. Major biotransformation routes of some allylamine antimycotics. In: Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: JR Prous Science Publishers SA, 1987; 479-495.
23. Kovarik JM, Kirkesselis Humbert H, Grass P, Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 1992; 126 (Suppl. 39): 8-13.
24. Samsoen M. Terbinafine (Lamisil®). The first oral fungistatic and fungicidal allylamine. Nouv Dermatol 1992; 11: 743-762.
25. Schatz F, Brautigam M, Dobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377-383.
26. Debruyne D, Ryckelynck J-P. Clinical Pharmacokinetics of fluconazole. Clin Pharmacokinet 1993; 24: 10-27.
27. Dudley MN. Clinical pharmacology of fluconazole. Pharmacotherapy 1990; 10 (Suppl.): 141S-145S.
28. Runne U, Orfanos SE. The human nail: structure, growth and pathological changes. Curr Probl Dermatol 1981; 9: 101-149.
29. Baran R, Dawber RPR. Investigations and some physicochemical properties of nails. In: Baran R, Dawber RPR, eds. Diseases of the Nails and Their Management. Blackwell Science, Oxford 1984; 81-104.
30. Parent D, Achten G, Stouffs-Vanhoof F. Ultrastructure of the normal human nail. Am J Dermatopathol 1985; 6: 529-535.
31. Baden HP, Kvedar JC. The Nail. Goldsmith, New York, 1992; 697-711.
32. Dawber RPR. The ultrastructure and growth of human nails. Arch Dermatol Res 1980; 269: 197-204.
33. Walters KA, Goldsmith LA, Fleming B. Permeability characteristics of the human nail plate. Intern J Cosmetics Sci 1983; 5: 231-246.
34. Zaias N. Onychomycosis. Dermatol Clinics 1985; 3/3: 445-460.
35. Hägermark O, Berlin A, Wallin I, Boréus LO. Plasma concentrations of griseofulvin in healthy volunteers and out-patients treated for onychomcyosis. Acta Dermatovenereol 1976; 56: 289-296.
36. Harris R, Jones HE, Artis WM. Orally administered ketoconazole: route of delivery to the human stratum corneum. Antimicrob Ag Chemoth 1983; 24: 876-882.
37. Cauwenbergh G. Skin kinetics of azole antifungal drugs. In: Borgers M, Hay R, eds. Current Topics in Medical Mycology (Vol 4). Rinaldi MG.Publications by Springer-Verlag, New York, 1992; 88-136.
38. Segal R, Trattner A, Alteras I, et al. Once-weekly treatment with oral ketoconazole for superficial fungal infections. J Am Acad Dermatol 1993; 28: 126-127.
39. Finlay AY, Lever LR, Thomas R, Dykes PJ. Nail matrix kinetics of oral terbinafine in onychomysosis and normal nails. J Dermatol Treat 1990; 1 (Suppl. 2): 51-54.
40. Dykes PJ, Thomas R, Finlay AY. Determination of terbinafine in nail samples during systemic treatment for onychomycoses. Br J Dermatol 1990; 123: 481-486.
41. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), hair and nails during and after 250 mg terbinafine orally once per day for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-126.
42. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126 (Suppl. 39): 28-32.
43. Finlay AY, Thomas R, Chawla M. Does the oral dosage of terbinafine influence its concentration in nail? Dermatology 2000, Vienna, 18-21 May 1993, Department of Dermatology, University of Vienna, Austria, p. 40.
44. Schatz F, Bräutigam M, Bobrowolski E, Effendi I, Haberl H, Mensing H, Weidinger G, Stutz A. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 10: 377-83.
45. Hay RJ. Pharmacodynamic and pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1992; 31 (Suppl. 2): 6-7.
46. Wildfeuer A, Faergemann J, Laufen H et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses I994; 37: 127-130.
47. Fraki J, Heikkila H, Kero M, et al. An open-label, non-comparative study of the efficacy and safety of fluconazole in the treatment of onychomycosis. Current Therapeutic Res 1997; 58: 481-491.
48. Faergemann J, Iaufen H. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toenails with fluconazole 150 mg once weekly. Acta Dermatol Venereol 1996; 76: 219-221.
49. Savin RC, Drake L, Bable D, Stewart DM et al. Pharmacokinetics of three once weekly doses (150, 300, and 450 mg) in distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 1998; 38: S110-116.
50. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-268.
51. Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed: an investigation in onychomycosis. Clin Exp Dermatol 1992; 16: 374-376.
52. Willemsen M, De Doncker P, Willems J, et al. Post-treatment itraconazole levels in the nail. J Am Acad Dermatol 1992; 26: 731-735.
53. De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy in onychomycosis: a pharmacokinetic/ pharmacodynamic investigation of monthly cycles of 1-week pulse with itraconazole. Arch Dermatol 1996; 132: 34-41.
54. De Doncker P. Itraconazole and terbinafine in perspective; from petridish to patient. 7th Congress of the European Academy of Dermatology and Venerology, Nice, France, 7-11 October 1998. Eur Acad Dermatol Venerol 1998; 11 (Suppl 2): 595-596.
55. Shou-Rong Song, Qiong Chen, Ruo-Yu Li, Duan-Li Wang. Itraconazole: its pharmacokinetics in treatment of onychomycosis. Departement of Dermatology, The first Hospital, Beijing, Medical University, China, 1995.
56. Clayton Y. Relevance of broad spectrum and fungicidal activity of antifungals in the treatment of dermatomycosis. Br J Dermatol 1994; 130 (Suppl. 43): 7-8.